Borosil Limited Reports 87% Surge in Q1 Profit, Plans New Manufacturing Facility 2 hours ago Today
Borosil Limited announced robust Q1 financial results with revenue increasing by 5.20% to ₹232.70 crore and profit after tax surging by 87.40% to ₹17.40 crore. The company's Non-Glassware segment showed the highest growth at 10.70%. Borosil plans to invest ₹40 crore in a new manufacturing facility for vacuum-insulated stainless steel bottles, with an annual capacity of 2.4 million units. The company aims for a 15-20% revenue CAGR and operates with an extensive distribution network of 250,000 retail outlets and 18,000+ distributors.
Borosil Targets 12-14% Revenue Growth Through Strategic Initiatives 5 days ago
Borosil Reports Q1 Loss of 42 Crore Rupees Amid Revenue Decline 7 days ago
Borosil Ltd's Q4 results show significant growth with net profit up 120% to ₹11.00 crore and revenue increasing 15.8% to ₹270.20 crore. EBITDA rose 95% to ₹37.20 crore, with margin improving to 13.75%. The board approved a 600 tonnes per day capacity expansion with a ₹950.00 crore investment.
02Apr 25
Borosil Expands Manufacturing Footprint with New Rajasthan Facility
Borosil Limited plans to set up a new manufacturing facility in Rajasthan through its subsidiary Stylenest India Limited. The unit will produce vacuum insulated stainless-steel products with an estimated capex of Rs. 40 crore and an annual production capacity of 2.40 million units. Expected to start commercial production by December 2025, this move aims to address BIS certification challenges, improve supply chain resilience, and align with the 'Make in India' initiative. The company also appointed Mr. Suresh Savaliya as the new Company Secretary and Compliance Officer.
Borosil Ltd achieved 17.1% YoY revenue growth for 9 months FY25, reaching ₹837.6 crores. Opalware segment grew 9%, glassware 22.9%, and non-glassware 17.8%. Q3 saw 11.3% revenue growth but 6.4% drop in net profit due to rising costs. EBITDA for 9 months FY25 increased 17.4% YoY to ₹140.2 crores with 17% margin. Challenges include new pharmaceutical marketing practices, e-commerce shift, and channel mix changes. Company focuses on product innovation, capacity expansion, and market growth strategies.